ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2184 entries already.
GHO Capital has closed its fourth fund, GHO Capital IV LP, raising over €2.5bn (~US$2.9bn) to invest in global healthcare. The fund brings the firm’s total assets under management to around €9bn, making it Europe’s largest healthcare-focused private equity firm.
Hemab Therapeutics A/S has completed an oversubscribed US$157m Series C financing round led by Sofinnova Partners to accelarate and expand its pipeline in bleeding disorders and thrombosis treatments.
The French AI-synbio specialist Abolis Biotechnologies SAS has entered a strategic €140m alliance with API manufacturer EuroAPI SA under the IPCEI Med4Cure funding programme. Within the collaboration, Abolis is developing production chassis for microbial corticosteroid manufacturing. The goal: to make Europe independent from imports from Asia.
VC investments in biotech rose 70.9% in Q3 2025 to US$3.1bn, driven by Series D growth, M&A activity, and Fed interest rate cuts, reports Global Data. J.P. Morgan reports same trends but different figures.
California-based biotech Electra Therapeutics Inc has secured US$183m in Series C financing. The investment comes from a consortium of four European investors and Mubadala Capital. Contrary to some reports, more SIRPα modulators exist than the investors initially indicated.
Pharma giant Ipsen will pay US$1bn to acquire French immuno-oncology firm ImCheck Therapeutics SAS. The deal includes US$350m upfront and up to US$650m in milestone payments. ImCheck focuses on butyrophilins, a new class of immune regulators, through its antibody programme ICT01, currently in Phase I trials.
Following its US$361 m Series C financing, Tubulis AG presented first Phase I/IIa data on its lead ADC, TUB-040, at ESMO 2025 in Berlin. The study focuseds on patients with platinum-resistant ovarian cancer (PROC). TUB-040 shows clear differentiation potential
Danish companies H. Lundbeck A/S (Lundbeck) and Contera Pharma A/S have inked a strategic research collaboration aiming at accelerating the development of oligonucleotide-based treatments for medically underserved neurological conditions.
The Merck subsidiary EMD Serono has agreed to price reductions of up to 84% for its in vitro fertilisation products in the United States. To avoid paying pharmaceutical tariffs, the company will distribute the products directly to self-paying patients via the TrumpRx.gov platform from 2026.
French ADC start-up Adcytherix SAS has added €105m Series A funding to a €30m seed financing round closed last year. With the money, the company will start a Phase I study with its lead ADCX-020 in Q1 2026 and develop novel payloads to break ADC therapy resistance.